Healthcare Business Review: Nu Skin’s Possible China Problem, Sucampo and Takeda Win With FDA
Shares of Nu Skin Enterprises Inc. (NYSE:NUS) slide on rumors that it might lose its license in China. If the chatter turns out to be correct, Usana Health Sciences, Inc. (NASDAQ:USNA) would likely be pulled down as well according to Citron Research, who says that the latter has endured as many if not more “China issues” than has Nu Skin.
Don’t Miss: Will Cable Kill the Console?
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) and Takeda Pharma (TKPYY.PK) report that the FDA has granted the status of priority review to their supplemental new drug application for an additional indication for Amitiza, which is a treatment for opioid-induced constipation in patients suffering from chronic, non-cancer pain. A ruling is expected by late January 2013.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>